Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 13 of 25
Real-time Sensorimotor Feedback for Injury Prevention Assessed in Virtual Reality
NCT02933008
Health Literacy Multi-media Study
NCT02999529
Effect of Upper Airway Stimulation on Vascular Function in Obstructive Sleep Apnea
NCT03051165
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT02897375
Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)
NCT02918773
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
NCT02858869
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
NCT02709083
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
NCT02765854
Disparities in National Kidney Allocation Policy
NCT02879812
Acupuncture for Postoperative Analgesia in Laparoscopic Surgery
NCT02940288
Healing Hearts and Mending Minds in Older Adults Living With HIV
NCT02711878
Dolutegravir in Reservoirs
NCT02924389
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
NCT02877082
HCR vs. CABG Study
NCT02892474
Blepharospasm Tools
NCT02780336
Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression
NCT03006393
Tailoring of Vaccine-Focused Messages: Moral Foundations
NCT02851459
Identification and Treatment of Diabetes In Solid Organ Transplant Recipients
NCT02605200
New Strategies to Assess Anal Cancer Risk In Women
NCT02873741
FACBC Prostate Therapy Response
NCT02830880
Autism MEAL Plan: Parent Training to Manage Eating Aversions & Limited Variety
NCT02712281
Fitbit for Postoperative Ambulation
NCT02833324
Magnetic Resonance Spectroscopy (MRS) in Midlife Depression
NCT02567110
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
NCT02876159
Turning Night Into Day: Transcontinental Provision of Telehealth By and For the Emory Community
NCT02895997
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
NCT02646982
Contemplative Well-being Apps for the Workplace
NCT03452670
To Enhance Breast Cancer Survivorship of Asian Americans
NCT02803593
Sitagliptin in Non-Diabetic Patients Undergoing General Surgery
NCT02741687
Smartphone Delivered In-home Cardiopulmonary Rehabilitation
NCT02791685
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
NCT02730195
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
NCT02701400
ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients
NCT02691221
Neurologic Injury Following Aortic Arch Replacement
NCT02750423
Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation
NCT02796755
Evaluating the Electro Magnetic Interference of Using Tablet and Smart Phone on Leadless Pacemaker (MICRA)
NCT02758210
Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
NCT02786147
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
NCT02630030
Physiological Augmentation of Mindfulness Meditation
NCT02754557
Integrated Eating Aversion Treatment Manual-Parent Version
NCT02721901
Technology-based Eye Care Services (TECS) Compare
NCT02558712
Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)
NCT02395289
Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes
NCT02749214
Arginine Therapy for Sickle Cell Disease Pain
NCT02536170
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
NCT02644460
Hearts and Minds in HIV
NCT02315742
Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer
NCT03220945
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
NCT02556918
Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery
NCT02443402
AiDing Diuresis wIth Tolvaptan (ADD-IT)
NCT02646540
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.